The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...

Brooks Running has a mega list of popular shoes on sale for less than $100. Shoppers can grab huge deals on shoes like the ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.